Innovative Immunotherapy Tactiva Therapeutics specializes in advanced cancer immunotherapies using dual T cell receptor technology, presenting opportunities to collaborate with biotech and pharma firms seeking cutting-edge treatment solutions for oncology.

Recent Funding Boost With a substantial Series A funding of $35 million secured in late 2018, Tactiva is positioned for further research and development, offering potential partnerships for investors and organizations interested in emerging biotech innovations.

Growing Market Presence Having launched novel autologous cellular immunotherapy and actively presenting preclinical data, Tactiva is gaining visibility in the biotech community, which could translate into opportunities for strategic partnerships, licensing, and research collaborations.

Targeted Oncology Focus Targeting a broad range of cancers through next-generation immunotherapies, Tactiva offers opportunities for organizations involved in specific oncology markets to explore complementary or co-development initiatives.

Small but Agile Team Despite a compact team of fewer than 10 employees, Tactiva demonstrates rapid development and innovation, creating possibilities for early-stage venture investors and service providers eager to engage with emerging biotech startups.